BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16737094)

  • 1. [Drug evaluation by the French National Health Authority for reimbursement decisions].
    Bouvenot G
    Bull Acad Natl Med; 2005 Nov; 189(8):1683-90; discussion 1690-1. PubMed ID: 16737094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Quantification of pharmacological progress by the French National Health Authorities].
    Bouvenot G
    Bull Acad Natl Med; 2006; 190(4-5):893-903; discussion 903-4. PubMed ID: 17195614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The French National Authority for Health].
    Degos L
    Bull Acad Natl Med; 2006 Oct; 190(7):1327-37; discussion 1337-8. PubMed ID: 17450670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The benefit provided by new medicinal products in 2005-2006--the viewpoint of the French National Authority for Health].
    Bouvenot G
    Therapie; 2007; 62(5):387-91. PubMed ID: 18206101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative added value: what are the tools to evaluate it?
    Le Jeunne C; Woronoff-Lemsi MC; David N; de Sahb R;
    Therapie; 2008; 63(2):113-7, 107-11. PubMed ID: 18561884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Access to medicines in France].
    Bouvenot G; Bouvenot J
    Bull Acad Natl Med; 2009 Mar; 193(3):649-59; discussion 659-62. PubMed ID: 19883016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Most innovative drugs labelled during the last years in paediatrics: does the paediatrician have the tools for their identification?].
    Autret-Leca E
    Arch Pediatr; 2010 Aug; 17(8):1237-42. PubMed ID: 20615673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical pricing and reimbursement reforms in Greece.
    Yfantopoulos J
    Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the medical value of a drug. A necessity for the Transparency Commission].
    Avouac B
    Therapie; 1992; 47(1):9-16. PubMed ID: 1523604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing cancer drugs for reimbursement: methodology, relationship between effect size and medical need.
    de Sahb-Berkovitch R; Woronoff-Lemsi MC; Molimard M;
    Therapie; 2010; 65(4):373-7, 367-72. PubMed ID: 20854761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real medical benefit assessed by indirect comparison.
    Falissard B; Zylberman M; Cucherat M; Izard V; Meyer F
    Therapie; 2009; 64(3):225-32. PubMed ID: 19671436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The French Biomedicine Agency and medically assisted reproduction].
    Camby C
    Bull Acad Natl Med; 2008 Jan; 192(1):17-21; discussion 21-2. PubMed ID: 18663978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National Authority for Health: France.
    Rochaix L; Xerri B
    Issue Brief (Commonw Fund); 2009 Jul; 58():1-9. PubMed ID: 19639712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prioritisation by physicians in the Netherlands--the growth hormone example in drug reimbursement decisions.
    de Bont A; Zandwijken G; Stolk E; Niessen L
    Health Policy; 2007 Mar; 80(3):369-77. PubMed ID: 16684580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of generic drug supply in France].
    Taboulet F; Haramburu F; Latry P
    Rev Epidemiol Sante Publique; 2003 Sep; 51(4):415-25. PubMed ID: 13679734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [French national health insurance. The current situation].
    Huguier M; Lagrave M; Marcelli A; Rossignol C; Tillement JP
    Bull Acad Natl Med; 2010 Jun; 194(6):1095-103. PubMed ID: 21513139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.